EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Rapid Regression of Choroidal Metastasis under First-Line Osimertinib Therapy in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Case Report

Hinrich J. Hufnagel, Oliver Zeitz, Farris Abdula, Antonia M. Joussen, Lynn S. zur Bonsen

Case Reports in Ophthalmology · 2026-09-07 · 17 (1) · 980-987

DOI: 10.1159/cop/acaag008 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Choroidal metastases may cause substantial visual impairment in patients with metastatic non-small cell lung cancer (NSCLC). Although local ocular treatments are frequently considered, targeted systemic therapy may provide effective control in tumors harboring actionable mutations. We report the rapid regression of a choroidal metastasis following first-line osimertinib therapy in a patient with epidermal growth factor receptor (EGFR)-mutated NSCLC. Case Presentation: A 59-year-old man with metastatic EGFR-mutated NSCLC presented with progressive visual decline in the left eye. Ophthalmic examination revealed a peripapillary choroidal lesion associated with serous retinal detachment. Optical coherence tomography demonstrated subretinal fluid, consistent with a choroidal metastasis. First-line osimertinib therapy had been initiated 12 days before presentation at our clinic. An early reduction in subretinal fluid was observed during follow-up, followed by complete resolution at the 2-month follow-up. This was accompanied by regression of the choroidal lesion and improvement in visual function. No local ocular treatment was required. Conclusion: First-line osimertinib may induce rapid regression of choroidal metastases in patients with EGFR-mutated NSCLC. In selected cases, an early response to systemic targeted therapy may allow local ocular treatment to be avoided.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →